These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25092743)

  • 1. The democratization of the oncogene.
    Le AT; Doebele RC
    Cancer Discov; 2014 Aug; 4(8):870-2. PubMed ID: 25092743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
    Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
    N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
    Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
    J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
    Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
    Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
    [No Abstract]   [Full Text] [Related]  

  • 7. Aggressive Metastatic Inflammatory Myofibroblastic Tumor After Allogeneic Stem Cell Transplant With Fatal Pulmonary Toxicity From Crizotinib.
    Shash H; Stefanovici C; Phillips S; Cuvelier GD
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):642-645. PubMed ID: 27271810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review.
    Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA
    Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
    Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
    Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.
    Mai S; Xiong G; Diao D; Wang W; Zhou Y; Cai R
    Lung Cancer; 2019 Feb; 128():101-104. PubMed ID: 30642440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
    Kazandjian D; Blumenthal GM; Luo L; He K; Fran I; Lemery S; Pazdur R
    Oncologist; 2016 Aug; 21(8):974-80. PubMed ID: 27328934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.
    Salvi S; Varesano S; Boccardo S; Ravetti JL; Canessa PA; Pistillo MP; Ferro P; Fedeli F; Roncella S
    J Thorac Oncol; 2017 Aug; 12(8):e116-e118. PubMed ID: 28748818
    [No Abstract]   [Full Text] [Related]  

  • 14. More on crizotinib.
    Orenstein JM
    N Engl J Med; 2011 Feb; 364(8):777; author reply 778-9. PubMed ID: 21345112
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
    Juan O; Popat S
    Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
    [No Abstract]   [Full Text] [Related]  

  • 20. [Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].
    Svaton M; Pešek M
    Klin Onkol; 2016; 29(1):63-5. PubMed ID: 26879065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.